Literature DB >> 21185794

Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee.

Marco Senzolo1, Oliviero Riggio, Massimo Primignani.   

Abstract

This review summarizes the document elaborated by the Italian Association for the Study of the Liver (AISF) ad hoc committee "Vascular disorders of the liver" on the primary circulatory liver diseases, which include Budd-Chiari syndrome, obstruction of the hepatic portion of the inferior vena cava, portal vein thrombosis, sinusoidal obstruction syndrome (veno-occlusive disease) and hereditary hemorrhagic telangiectasia. A characteristic of the primary circulatory liver diseases is that portal hypertension usually precedes liver dysfunction. Significant overlap exists amongst the diseases and risk factors that predispose patients to the primary circulatory liver diseases, though the pathogenesis of individual diseases varies. Management of the different vascular disorders is very peculiar and often multidisciplinary and patients should be referred to a tertiary referral centre for optimal care.
Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185794     DOI: 10.1016/j.dld.2010.11.006

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  15 in total

1.  Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?

Authors:  Aaron Liew; James Douketis
Journal:  Intern Emerg Med       Date:  2016-05-23       Impact factor: 3.397

Review 2.  Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult.

Authors:  Fania Puccia; Vania Lombardo; Lydia Giannitrapani; Anna Licata; Giovanni Mazzola; Maurizio Soresi
Journal:  J Ultrasound       Date:  2017-02-27

Review 3.  Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes.

Authors:  Francesco Vizzutti; Filippo Schepis; Umberto Arena; Fabrizio Fanelli; Stefano Gitto; Silvia Aspite; Laura Turco; Gabriele Dragoni; Giacomo Laffi; Fabio Marra
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

4.  Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Nicola Alessi; Giuseppe Cabibbo; Daniela Cabibi
Journal:  World J Hepatol       Date:  2013-05-27

Review 5.  Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis.

Authors:  Xingshun Qi; Valerio De Stefano; Chunping Su; Ming Bai; Xiaozhong Guo; Daiming Fan
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

Review 6.  Splanchnic Vein Thrombosis: Current Perspectives.

Authors:  Emanuele Valeriani; Nicoletta Riva; Marcello Di Nisio; Walter Ageno
Journal:  Vasc Health Risk Manag       Date:  2019-10-22

7.  Transjugular intrahepatic portosystemic shunt in the treatment of portal vein thrombosis: a critical review of literature.

Authors:  Xingshun Qi; Guohong Han
Journal:  Hepatol Int       Date:  2011-12-01       Impact factor: 6.047

8.  Small hepatic veins Budd-Chiari syndrome.

Authors:  Oliviero Riggio; Chiara Marzano; Alessia Papa; Chiara Pasquale; Maria Ludovica Gasperini; Antonietta Gigante; Dominique Charles Valla; Aurélie Plessier; Antonio Amoroso
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

9.  Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome.

Authors:  Chun-Ze Zhou; Rui-Feng Wang; Wei-Fu Lv; Yu-Qin Fu; De-Lei Cheng; Yi-Jiang Zhu; Chang-Long Hou; Xian-Jun Ye
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

Review 10.  Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician.

Authors:  Stefania Basili; Daniele Pastori; Valeria Raparelli; Francesco Violi
Journal:  Therap Adv Gastroenterol       Date:  2018-09-06       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.